June 2019 | New FDA 483s
In June of 2019, we added 180 FDA 483s to our database of 27,500+ FDA inspection documents.
Jessica Strmiska
July 24, 2019
In June of 2019, we added 180 FDA 483s to our database of 27,500+ FDA inspection documents.
Former FDA Investigator Peter Baker gives insight to MHRA’s GXP guide for data integrity.
GMP expert Barbara W. Unger provides her assessment of CDER’s State of Pharmaceutical Quality Report.
Three warning letters were posted this week in the areas we cover: two for drugs and one for device GMP violations. Akorn also announced that they received a warning letter but it has not yet been published.
Can mindfulness influence data integrity? Discover the insights Julie Maurhoff, a Senior Director of GxP Compliance and Inspection Readiness at Ultragenyx Pharmaceutical, gained after researching the topic.
Unlike last week, warning letter enforcement is sparse this week with only one drug GMP warning letter, none to compounding pharmacies and none to device firms.
In May of 2019, we added 262 FDA 483s to our database of 27,500+ FDA inspection documents.
This was a busy week in contrast to the past two weeks in terms of posted warning letters. Seven drug warning letters and one device warning letter were posted.
Preparing for GMP inspections, particularly pre-approval inspections, can be a challenge when resources are limited and staff may have little expertise in these important activities.
CONTACT US: 844-332-3320 | info@fdazilla.com
Can’t find what you are looking for? Contact us.
SEARCH LESS KNOW MORE
The essential tool for compliance, regulatory, and quality professionals